In the last 90 days, Royalty Pharma plc insiders filed 0 open-market purchases and 5 sales; 651 institutions reported holding it in 13F filings for Q2 2026, worth $20.6B in total; Dorsey Asset Management is the only superinvestor holding it.
SEC filings
10-K, 10-Q, 8-K, 20-F and 40-F reports Royalty Pharma plc filed with the SEC, newest first.
Livermore lists each filing's form, 8-K items and dates only. To read a filing, open it on SEC.gov; an 8-K's press release or other attachments, such as exhibit 99.1 for Item 2.02, are in the filing index.
1.01Item 1.01: Entry into a material definitive agreement2.03Item 2.03: New direct financial obligation, such as new debt or an off-balance-sheet obligation9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement2.01Item 2.01: Completion of an acquisition or disposition of assets2.03Item 2.03: New direct financial obligation, such as new debt or an off-balance-sheet obligation5.02Item 5.02: Departure or appointment of directors or officers; executive pay arrangements5.03Item 5.03: Amendment to the articles of incorporation or bylaws; change in fiscal year9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement3.02Item 3.02: Unregistered sale of equity securities7.01Item 7.01: Regulation FD disclosure9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement5.03Item 5.03: Amendment to the articles of incorporation or bylaws; change in fiscal year9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement2.03Item 2.03: New direct financial obligation, such as new debt or an off-balance-sheet obligation9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement2.03Item 2.03: New direct financial obligation, such as new debt or an off-balance-sheet obligation9.01Item 9.01: Financial statements and exhibits
